Leonard A Jason1, John Kalns2, Alicia Richarte2, Ben Z Katz3, Chelsea Torres1. 1. Center for Community Research, DePaul University, Chicago, IL. 2. Hyperion Biotechnology, Inc., San Antonio, TX. 3. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.
Abstract
OBJECTIVE: The prevalence of pediatric Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) has been estimated from an ethnically and sociodemographically diverse community-based random sample of 10,119 youth aged 5-17. A team of physicians made a final diagnosis of ME/CFS if the participants met criteria for up to three selected case definitions following medical and psychiatric evaluations. We assessed whether a salivary biomarker of fatigue could identify youth with ME/CFS. STUDY DESIGN: We examined the ratio of the concentrations of 2 peptide fragments in saliva, referred to as the Fatigue Biomarker Index (FBI), in participants from our study diagnosed with ME/CFS (n=59) and matched controls (n=39). RESULTS: Significant overall differences were found in the FBI between those participants with severe ME/CFS and those with ME/CFS and the controls. CONCLUSIONS: If confirmed in other populations, the FBI could serve as an objective test to aid in the diagnosis of severe ME/CFS.
OBJECTIVE: The prevalence of pediatric Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) has been estimated from an ethnically and sociodemographically diverse community-based random sample of 10,119 youth aged 5-17. A team of physicians made a final diagnosis of ME/CFS if the participants met criteria for up to three selected case definitions following medical and psychiatric evaluations. We assessed whether a salivary biomarker of fatigue could identify youth with ME/CFS. STUDY DESIGN: We examined the ratio of the concentrations of 2 peptide fragments in saliva, referred to as the Fatigue Biomarker Index (FBI), in participants from our study diagnosed with ME/CFS (n=59) and matched controls (n=39). RESULTS: Significant overall differences were found in the FBI between those participants with severe ME/CFS and those with ME/CFS and the controls. CONCLUSIONS: If confirmed in other populations, the FBI could serve as an objective test to aid in the diagnosis of severe ME/CFS.
Authors: J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-07 Impact factor: 8.829
Authors: Anna Kuo; Joshua J Todd; Jessica W Witherspoon; Tokunbor A Lawal; Jeffery Elliott; Irene C Chrismer; Monique O Shelton; Muslima S Razaqyar; Minal S Jain; Ruhi Vasavada; Melissa Waite; Bart Drinkard; Darren Michael; Alicia Richarte; Carsten G Bönnemann; Katherine G Meilleur Journal: J Neuromuscul Dis Date: 2019
Authors: Ben Z Katz; Caroline Reuter; Yair Lupovitch; Kristen Gleason; Damani McClellan; Joseph Cotler; Leonard A Jason Journal: J Pediatr Date: 2019-03-08 Impact factor: 4.406